SOURCE: Basilea Pharmaceutica AG

July 17, 2007 01:20 ET

Basilea Announces Filing of New Drug Submission in Canada for Ceftobiprole

BASEL, SWITZERLAND--(Marketwire - July 17, 2007) -


Basel, Switzerland, July 17, 2007 - Basilea Pharmaceutica Ltd. (SWX: BSLN) announced today the filing of a New Drug Submission (NDS) for ceftobiprole with the Therapeutic Products Directorate (TPD) of Health Canada by its license partner Janssen-Ortho, Inc., a Johnson & Johnson company. This submission is for the use of ceftobiprole in the treatment of complicated skin and skin structure infections (cSSSI).

Market applications for the use of ceftobiprole in the treatment of severe skin infections have also been filed in the U.S. by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and in Europe by Janssen-Cilag International NV.

Ceftobiprole is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International.

About Basilea

Basilea Pharmaceutica Ltd. is an independent biopharmaceutical company headquartered in Basel, Switzerland, and listed on the SWX Swiss Exchange (SWX: BSLN). Basilea is currently focused on the development of new antibacterial, antifungal and dermatology drugs.

Disclaimer

This communication is intended for information to the financial community only (investors and/or potential investors and their advisors) and expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.


For further information, please contact:

+----------------------------------------------------------+
| General Information     | Investor Relations             |
|-------------------------+--------------------------------|
| information@basilea.com | Dr. Barbara Zink               |
|                         | investor_relations@basilea.com |
+----------------------------------------------------------+


This press release can be downloaded from www.basilea.com

The press release can also be downloaded from the following link:

http://hugin.info/134390/R/1140022/215119.pdf

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information